ArticleNature communications2014
Rapid in vivo detection of isoniazid-sensitive Mycobacterium tuberculosis by breath test.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Aptamer-Based Detection of Ampicillin in Urine Samples.Antibiotics (Basel, Switzerland) · 2020Article
- Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.The Journal of antibiotics · 2018Article
- Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature.Expert opinion on therapeutic patents · 2016Review
- Ultrasensitive multiplex optical quantification of bacteria in large samples of biofluids.Scientific reports · 2016Article
- Detecting virulence and drug-resistance mycobacterial phenotypes in vivo.Trends in microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
There is urgent need for rapid, point-of-care diagnostic tools for tuberculosis (TB) and drug sensitivity. Current methods based on in vitro growth take weeks, while DNA amplification can neither differentiate live from dead organisms nor determine phenotypic drug resistance. Here we show the development and evaluation of a rapid breath test for isoniazid (INH)-sensitive TB based on detection of labelled N2 gas formed specifically from labelled INH by mycobacterial KatG enzyme. In vitro data show that the assay is specific, dependent on mycobacterial abundance and discriminates between INH-sensitive and INH-resistant (S315T mutant KatG) TB. In vivo, the assay is rapid with maximal detection of (15)N2 in exhaled breath of infected rabbits within 5-10 min. No increase in (15)N2 is detected in uninfected animals, and the increases in (15)N2 are dependent on infection dose. This test may allow rapid detection of INH-sensitive TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.